Bolt Biotherapeutics (BOLT : NASDAQ)
Common Stock
$6.27
USD
+2.08 (49.64%)
Last updated: 2026-10-23
Follow BOLT
BOLT
Bolt Biotherapeutics
WealthAwesomePerformance
1 Day
+49.64%
1 Week
+56.75%
1 Month
+71.78%
YTD
+48.93%
Key Statistics
Market Cap
$14.78M
52W High
$7.78
52W Low
$3.10
P/E Ratio
-
50 Day MA
$3.81
200 Day MA
$4.49
Beta
1.01
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/23/2026 | $6.98 | $7.78 | $5.99 | $6.27 | $6.27 | 12,882,703 |
| 10/22/2026 | $4.06 | $4.21 | $4.03 | $4.19 | $4.19 | 14,054 |
| 10/21/2026 | $4.33 | $4.48 | $4.05 | $4.14 | $4.14 | 34,466 |
| 10/20/2026 | $4.05 | $4.33 | $4.05 | $4.31 | $4.31 | 29,274 |
| 10/19/2026 | $3.95 | $4.20 | $3.95 | $4.04 | $4.04 | 21,942 |
| 10/16/2026 | $4.46 | $4.48 | $3.96 | $4.00 | $4.00 | 10,118 |
| 10/15/2026 | $4.14 | $4.44 | $3.85 | $4.24 | $4.24 | 9,254 |
| 10/14/2026 | $4.28 | $4.38 | $3.76 | $3.98 | $3.98 | 31,069 |
| 10/13/2026 | $4.26 | $4.38 | $4.25 | $4.29 | $4.29 | 12,653 |
| 10/12/2026 | $4.13 | $4.68 | $4.13 | $4.24 | $4.24 | 28,728 |
Analyst Price Targets
Based on 4 analysts covering BOLT · as of Oct 26, 2026
Wall Street analysts forecast BOLT stock price to rise 553.9% over the next 12 months.
Consensus
Buy4.00 / 5.00
Avg. Target
US$41.00
+553.9% Upside
Previously US$29.00 on Oct 5, 2026
Current Price
US$6.27
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BOLT's historical volatility
30-Day Vol
138.1%
Annualized
90-Day Vol
99.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$7.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$6.65 | US$4.13 – US$10.72 |
| 60 trading days | US$7.06 | US$3.60 – US$13.86 |
| 90 trading days | US$7.50 | US$3.28 – US$17.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Financials
- Revenue (TTM)
- $4.70M
- EBITDA
- $-27.56M
- Profit Margin
- 0.00%
- ROE (TTM)
- -111.65%
- EPS (Diluted)
- -16.51
- Book Value
- 6.56
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About BOLT.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SBFM | Sunshine Biopharma Inc | $3.00 | +1696.41% |
| HCTI | Healthcare Triangle Inc | $6.71 | +1672.79% |
| PPCB | Propanc Biopharma, Inc. Common Stock | $2.80 | +921.90% |
| BDRX | Biodexa Pharmaceticals | $3.39 | +717.97% |
| NVNWF | Nvni Group Limited | $0.00 | +193.75% |
| RITRF | Reitar Logtech Holdings Limited | $0.03 | +78.57% |
| CLRO | ClearOne Inc | $3.25 | +69.27% |
| ESLA | Estrella Immunopharma Inc. | $0.98 | +35.53% |